Shares of Cascadian Therapeutics, Inc. (NASDAQ:CASC) have earned an average rating of “Hold” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $6.00.

CASC has been the topic of several recent analyst reports. Cowen and Company restated a “buy” rating on shares of Cascadian Therapeutics in a report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Monday, July 17th. Cantor Fitzgerald restated a “hold” rating and set a $4.00 price objective on shares of Cascadian Therapeutics in a report on Thursday, August 31st. ValuEngine downgraded shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, Barclays PLC initiated coverage on shares of Cascadian Therapeutics in a report on Wednesday, September 6th. They set an “underweight” rating and a $4.00 price objective on the stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/cascadian-therapeutics-inc-casc-receives-consensus-rating-of-hold-from-analysts/1616501.html.

Shares of Cascadian Therapeutics (CASC) opened at 4.39 on Friday. Cascadian Therapeutics has a one year low of $3.18 and a one year high of $9.18. The stock’s 50 day moving average is $3.82 and its 200-day moving average is $3.92. The stock’s market cap is $221.93 million.

Cascadian Therapeutics (NASDAQ:CASC) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.06. During the same quarter last year, the company posted ($1.57) EPS. On average, equities analysts forecast that Cascadian Therapeutics will post $5.02 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System purchased a new stake in Cascadian Therapeutics in the second quarter valued at approximately $226,000. State Street Corp boosted its position in Cascadian Therapeutics by 1,113.7% in the second quarter. State Street Corp now owns 411,299 shares of the biopharmaceutical company’s stock valued at $1,527,000 after buying an additional 377,410 shares during the last quarter. OxFORD Asset Management LLP boosted its position in Cascadian Therapeutics by 11.8% in the second quarter. OxFORD Asset Management LLP now owns 181,323 shares of the biopharmaceutical company’s stock valued at $674,000 after buying an additional 19,131 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Cascadian Therapeutics by 203.7% in the second quarter. Dimensional Fund Advisors LP now owns 97,880 shares of the biopharmaceutical company’s stock valued at $364,000 after buying an additional 65,651 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Cascadian Therapeutics by 24.1% in the second quarter. Vanguard Group Inc. now owns 1,767,681 shares of the biopharmaceutical company’s stock valued at $6,567,000 after buying an additional 343,838 shares during the last quarter. Hedge funds and other institutional investors own 82.55% of the company’s stock.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Analyst Recommendations for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.